PDS Biotechnology (NASDAQ:PDSB) Stock Rating Upgraded by Wall Street Zen

PDS Biotechnology (NASDAQ:PDSB) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

PDSB has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of PDS Biotechnology in a research note on Wednesday, April 15th. Weiss Ratings restated a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Price Performance

PDSB stock opened at $0.78 on Friday. The stock has a 50-day moving average price of $0.86 and a two-hundred day moving average price of $0.87. PDS Biotechnology has a 1 year low of $0.51 and a 1 year high of $1.55. The stock has a market cap of $43.35 million, a PE ratio of -1.16 and a beta of 1.62. The company has a current ratio of 2.26, a quick ratio of 2.26 and a debt-to-equity ratio of 2.73.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.02. Equities analysts forecast that PDS Biotechnology will post -0.52 EPS for the current fiscal year.

Institutional Investors Weigh In On PDS Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC acquired a new stake in PDS Biotechnology in the fourth quarter valued at approximately $2,182,000. BlackRock Inc. bought a new stake in shares of PDS Biotechnology during the second quarter valued at approximately $535,000. Squarepoint Ops LLC raised its position in shares of PDS Biotechnology by 116.1% during the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock worth $295,000 after purchasing an additional 156,662 shares during the period. Commonwealth Equity Services LLC raised its position in shares of PDS Biotechnology by 117.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock worth $151,000 after purchasing an additional 106,300 shares during the period. Finally, Susquehanna International Group LLP lifted its holdings in shares of PDS Biotechnology by 603.7% in the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after purchasing an additional 80,937 shares in the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.